Top Bioinformatics Startups in 2026

H1 was built by scientists for scientists. We empower stakeholders at healthcare and life science companies to make smarter scientific decisions by providing access to critical data through an intuitive interface. Working with some of the largest and most influential global life science organizations, H1 provides insight into thought leaders, scholarly content, academics, and healthcare professionals with much more on the way.

DNAnexus is a software technology company that aims to be the DNA data platform of the future. Fueled by technological advances spanning biochemistry, microfabrication, optics, and high-performance systems design, DNA sequencing is advancing at an unprecedented rate of approximately 10-fold improvement in cost and throughput every 18 months. As a result, data output and compute requirements have vastly outstripped Moore's law, shifting the bottleneck toward the data management challenges. Soon it will be possible to sequence a full human genome for well under $1,000, making sequencing the first million genomes commercially viable, but will require compute infrastructure on the order of 100,000 CPUs and Exabytes of storage.

Our CapsidMap™ platform uses AI to systematically and rapidly optimize AAV capsids, overcoming the limitations of naturally occurring virus capsids by improving targeting ability, payload size, immune evasion and manufacturability. By building a massive and detailed map of synthetic AAV capsid sequence space, we can quickly navigate the landscape to find enhanced gene therapy vectors with transformative potential.

Maybe you’ve supported a friend or family member who’s dealing with cancer. Maybe you’ve battled it yourself. At Syapse, our mission is to enable healthcare providers to deliver the best care to every cancer patient through precision medicine and it's our personal connections to this mission that unites us Together, we're building a revolutionary suite of products that integrate complex oncology data and share insights across the cancer care ecosystem including cancer care centers and life science companies developing the next generation of cancer diagnostics and medicines. Join us in our exciting mission to scale precision medicine to reach every cancer patient on the planet. All while making a positive impact in the lives of people battling cancer, their families and the organizations committed to their care.

We provide the industry’s only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need. By joining Viome, you are joining a revolutionary movement. A movement that – for the first time in human history – will make becoming ill a matter of choice, and not simply bad luck. Scientists have worked for over a decade to develop this technology that offers unprecedented visibility into your body. With this, we can create a unique profile of the biochemistry and ecosystem inside of you, and make personalized, actionable, and adaptive recommendations for your health. Our at-home tests are not just one-time tests, but your true health companion, enabling you to monitor your health over time. Your results and recommendations adapt to your changing ecosystem so you are always aware and taking action towards maximizing your vitality and lifespan. The Viome team is made up of scientists, engineers, researchers and entrepreneurs who are passionate about radically improving the wellness of our customers.

At IndieBio, we are committed to building a future where biology is not only a field of study, but a technology that will help solve our world’s most challenging problems. We are part of SOSV, one of the world's top early-stage investors, and our three-month programs are designed to put founders side-by-side every day with technical experts as well as provide $500,000 in capital to ensure a fast start for world shaping ideas. Graduates of IndieBio benefit from the remarkable IndieBio community as well as well as ongoing SOSV investment through A, B and later rounds. We have locations in New York City and San Francisco. If you are driven to change the world around you, then stop waiting: APPLY NOW!

Lifebit is a leading innovator in bioinformatics software solutions and AI. In 2021, the London, UK based company closed its Series B funding round of US$60M led by Tiger Global, to fuel ongoing product innovations and global market expansion. Lifebit is pushing forward the frontiers of health and knowledge by democratising access to, and powering analyses of, omics big data. We are the pioneers revolutionising bioinformatics and biomedical data analysis. The company’s flagship product, Lifebit CloudOS, is fast becoming the industry’s standard for unified and secure research over distributed big data. On top of its core foundation, the platform provides integration to open-source analysis and visualisation tools, as well as a marketplace of proprietary ones, a powerful data and cohort browser, and advanced AI functionality that together are powering discoveries in drug discovery and vaccine development. Top tier pharmaceutical organisations, global research institutes, and bioinformatics companies the world over are deploying Lifebit CloudOS. In April 2020 we closed our Series A funding round with tremendous support from new and previous investors. Based in London, UK, Lifebit is a diverse team spanning Europe and North America, with each person empowered and involved in every aspect of the business.

Our mission is to harness advanced technologies to increase our understanding of the biology that underlies lifespan, and to seek interventions that enable people to lead longer and healthier lives. We bring together scientists and technologists, thinkers and tinkerers, to explore the fundamental biology of aging. At Calico, you'll work closely with scientists to help ask big scientific questions, and invent software to help answer them. We're part of the Alphabet family, which includes Google, Verily, Waymo, and other companies.

Genomics is transforming medicine but data analysis and interpretation are the biggest bottlenecks. Basepair’s mission is for scientists, physicians, and ultimately people to extract actionable insights from genomic data to help with healthcare research, drug discovery, and personal health decisions. Basepair is an enterprise B2B SaaS for analytics and visualization of genomics data. Our customers include biopharma, molecular diagnostics, services, and some of the world’s top medical hospitals, e.g., Harvard Medical School, Stanford Univ, etc. We are funded by VCs, angel investors and have a front-row seat for the latest breakthroughs in life sciences.